glp-1 drugs kidney disease Current receptor agonists and recommendations in patients with FDA clears use of Ozempic

However, this patient group also had higher diastolic blood pressure compared with the other randomized patient group at the beginning of the first treatment (see Supplemental Table 1

Looking at the experience of patients in the Arcadia database, we see that while over 1,000,000 individuals filled a prescription for these agents between 2022 and 2024, only 34% remained on the therapy after 6 months

There are also longer-acting versions being studied, and pills specifically designed for weight loss (not just diabetes)

Galderisi S, De Hert M, Del Prato S, Fagiolini A, Gorwood P, Leucht S, et al

Are compounded GLP-1 drugs safe

Oprea, A